Skip to main content
. 2020 Oct 6;11(12):2791–2827. doi: 10.1007/s13300-020-00921-y

Table 3.

Frequently observed adverse events with sodium-glucose cotransporter 2 inhibitors: evidence from meta-analyses

Adverse events Overall SGLT2i [100] Empagliflozin [58] Canagliflozin [98] Dapagliflozin [99]
Acute kidney injury RR 0.59 (95% CI 0.39–0.89; I2 = 0.0%) Not analyzed Not analyzed Not analyzed
Diabetic ketoacidosis RR 0.66 (95% CI 0.30–1.45, I2 = 0.0%) Not analyzed Not analyzed Not analyzed
Urinary tract infections RR 1.02 (95% CI 0.95–1.09, I2 = 0.0%) OR 1.119 (95% CI 0.886–1.411)

Cana 100 mg: RR 1.45 (95% CI 0.91–2.29, p = 0.12)

Cana 300 mg: RR 1.18 (95% CI 0.73–1.91, p = 0.49)

 RR 1.74 (95% CI 1.21–2.49, p = 0.003)
Genital tract infections Not analyzed OR 2.814 (95% CI 1.712–4.625)

Cana 100 mg: RR 3.79 (95% CI 2.05–7.01, p < 0.01)

Cana 300 mg: RR 3.99 (95% CI 2.16–7.35, p   < 0.01)

 RR: 3.52 (95% CI 2.06–6.03, p < 0.00001)
Bone fractures RR 0.87 (95% CI 0.69–1.09, I2 = 1.3%) Not analyzed Not analyzed Not analyzed
Osmotic diuresis-related AE/hypovolemia Not analyzed Not analyzed

Cana 100 mg: RR 5.35 (95% CI 2.43–11.77, p < 0.01)

Cana 300 mg: RR 5.35 (95% CI 2.43–11.77, p < 0.01)

 RR: 0.74 (95% CI 0.32–1.71, p = 0.47)

AE Adverse events, OR odds ratio, RR relative risk, SGLT2i sodium-glucose cotransporter 2 inhibitors